Benjamin Slane, MD
Radiation Oncology · Lawrence, KSNPI 1376705871
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 20 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Novocure Inc. accounts for 61.1% of it on its own, with 5 other manufacturers making up the rest. 2025 is the largest year on record at $149, 3.9 times the $39 reported in 2019. That places this record below the midpoint for radiation oncology clinicians in KS, where the typical reported total is $776.
Across 20 payments — averaging $20.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novocure Inc.$245
- Myriad Genetic Laboratories, Inc.$70
- Boston Scientific$24
- Tactile Systems Technology Inc$24
- Progenics Pharmaceuticals, Inc.$23
- Johnson & Johnson$14
What the payments were for
- Food & beverage$402100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novocure Inc. | 13 | $245 |
| Myriad Genetic Laboratories, Inc. | 3 | $70 |
| Boston Scientific | 1 | $24 |
| Tactile Systems Technology Inc | 1 | $24 |
| Progenics Pharmaceuticals, Inc. | 1 | $23 |
| Johnson & Johnson | 1 | $14 |
How this compares
$402 in reported general payments places this provider in the 35th percentile of 54 radiation oncology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 123 | $1,741 |
| Oxybutynin Chloride ErOxybutynin Chloride | 23 | $307 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Lawrence
- Darren KlishLawrence$456
- Ajay TejwaniLawrence$250
- Ronald ChenKansas City$31K
- Xinglei ShenKansas City$16K
- David BryantWichita$15K
- Mark ThompsonOverland Park$9K
- David AkhavanKansas City$9K
- Fen WangKansas City$7K
- Joshua WeirWichita$6K
- Vickie MasseyOverland Park$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.